The purpose of this is to formally assess health literacy and medication adherence in participants with Inflammatory bowel disease (IBD). The study also aims to improve medication adherence, health-related quality of life, and disease activity through a 24-week intervention.
The purpose of this study is to formally assess health literacy and medication adherence in participants with Inflammatory bowel disease (IBD). The study also aims to improve medication adherence, health-related quality of life, and disease activity through a 24-week intervention that will include telephone reminders, educational materials, visits to the physician, and financial counseling.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
77
Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
The Emory Clinic
Atlanta, Georgia, United States
Change in Medication Possession Ratio (MPR)
The Medication possession Rate (MPR) will be calculated as the amount of medication consumed divided by days in the interval and adherence will be defined as greater than 80%.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Modified Morisky Adherence Scale-8 (MMAS-8) Score
MMAS-8 is an 8-item scale that has been validated to measure adherence in IBD patients (scoring details are claimed as proprietary information by the scale's copyright holder).
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Harvey Bradshaw Index (HBI) Score
The HBI is a self-administered questionnaire that assesses IBD severity. A score of less than 5 is generally considered to represent clinical remission. A score of 8 to 9 or higher are considered severe disease.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Simple Colitis Activity Index (SCAI) Score
The SCAI is a way of scoring disease activity in Ulcerative Colitis based on six simple questions about symptoms that gives a number between 0-19 that corresponds to the severity of disease activity. This index gives more detailed information on how active disease is using a number.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a health-related quality of life tool measuring physical, social, and emotional status. Scores range from 10-70. A lower score indicates poor quality of life while a higher score indicates greater quality of life.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
Change in Hospital Anxiety and Depression Scale (HADS) Score
The Hospital Anxiety and Depression Scale (HADS) is a fourteen item scale that asks participants to describe how they feel. Scores range between 0 and 21. A score of 0 to 7 is normal. A score of 8 to 10 indicates borderline depression/anxiety. A score of 11-21 indicates a case of depression/anxiety.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Disease Activity Assessed by the Number of Admissions
Individual participant data will be collected regarding the number of admissions to monitor IBD remission or progression.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Disease Activity Assessed by the Number of Clinic Visits
Individual participant data will be collected regarding the number of clinic visits to monitor IBD remission or progression.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Disease Activity Assessed by the Number of Emergency Visits
Individual participant data will be collected regarding the number of emergency room visits to monitor IBD remission or progression.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)
Change in Disease Activity Assessed by the Number of Surgeries
Individual participant data will be collected regarding the number of surgeries to monitor IBD remission or progression.
Time frame: 12 Weeks, End of Study (Up to 24 weeks)